abstract: To evaluate the prevalence and prognostic significance of @entity4854 in @entity583 , we studied 700 @entity1 (mean age 63.3 +/- 10.97) subsequently admitted to the UCIC of Tradate Hospital during the period January 1976 to December 1987. @entity1 were followed up for a median period of four years. On the basis of fasting @entity1503 values in the first five days of hospitalization, excluding the admission day, @entity1 were divided into groups: 401 @entity1 (57.0%) with constantly normal glycaemia; 84 @entity1 (12.0%) with glycaemia equal or superior to 120 mg/100 ml, and with subsequent normalization; and 215 @entity1 (31.0%) with @entity6 diagnosed before hospitalization and/or with persistent hyperglycaemia. The overall mortality was 284 (40.5%) and @entity65 were 90.8%. Within the first month of @entity583 98 @entity1 died. The mortality rate was 9.4% in normoglycaemic @entity1 and 20.2% in transient hyperglycaemic @entity1 , similar to the value observed in @entity6 @entity1 (20.0%). During the follow-up 186 @entity1 died. Late mortality after the first month is higher in @entity6 @entity1 (40%) and @entity1 with transient hyperglycaemia (37%) compared to normoglycaemic @entity1 (25.3%). Multivariate analysis shows that independent predictive variables are: for mortality in the first month, Killip class only; and after the first month, Killip class, metabolic classification, sex and @entity943 . The present study shows that transient hyperglycaemia has a low prevalence in the first days of @entity583 . Transient hyperglycaemia could be attributed not only to increased sympathetic tone elicited by @entity583 , but is probably a pathologic condition with an adverse outcome to which multiple factors contribute.

title: [Transient @entity4854 in acute XXXX : the short- and long-term risk factor for mortality].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes mellitus']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['blood glycaemia']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'acute myocardial infarction']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['supraventricular arrhythmias']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular deaths']

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarct']


abstract: BACKGROUND: Angiogenesis, the formation of new blood vessels, is essential for @entity5 growth. The inhibition of angiogenesis is therefore emerging as a promising therapy for @entity5 . Two natural products, @entity19525 and @entity36232 , were discovered to be potent inhibitors of angiogenesis due to their inhibition of endothelial cell proliferation. An analog of @entity19525 , @entity10822 , is currently undergoing clinical trials for the treatment of a variety of @entity5 . The underlying molecular mechanism of the inhibition of angiogenesis by these natural drugs has remained unknown. RESULTS: Both @entity10822 and @entity36232 bind to a common bifunctional protein, identified by mass spectrometry as the type 2 @entity1853 aminopeptidase ( @entity36231 ). This protein also acts as an inhibitor of eukaryotic initiation factor 2alpha (elF-2alpha) phosphorylation. Both drugs potently inhibit the @entity1853 aminopeptidase activity of @entity36231 without affecting its ability to block elF-2alpha phosphorylation. There are two types of @entity1853 aminopeptidase found in eukaryotes, but only the type 2 enzyme is inhibited by the drugs. A series of analogs of @entity19525 and @entity36232 were synthesized and their potency for inhibition of endothelial cell proliferation and inhibition of @entity1853 aminopeptidase activity was determined. A significant correlation was found between the two activities. CONCLUSIONS: The protein @entity36231 is a common molecular target for both @entity10822 and @entity36232 . This finding suggests that @entity36231 may play a critical role in the proliferation of endothelial cells and may serve as a promising target for the development of new anti-angiogenic drugs.

title: XXXX aminopeptidase (type 2) is the common target for angiogenesis inhibitors @entity10822 and @entity36232 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'cancer']

entities_list: @entity1853 :: ('MESH:D008715', 'Chemical') :: ['methionine']

entities_list: @entity19525 :: ('MESH:C026211', 'Chemical') :: ['fumagillin']

answer: @entity1853 :: (MESH:D008715,Chemical) :: ['Methionine']


abstract: Human Leucocyte Antigen (HLA) alleles, cytokine polymorphisms and the type of @entity2801 ( @entity2801 ) gene mutation are among predisposing factors for inhibitors (inh) development in @entity1 with severe @entity447 ( @entity447 ). The aim was to investigate the correlations among (i) @entity2801 gene intron-22 inversion, (ii) HLA alleles and haplotypes and (iii) certain cytokine polymorphisms, with the risk for @entity2801 inhibitors development in 52 Greek severe @entity447 @entity1 , exclusively treated with recombinant concentrates. We performed Long-Range PCR for detection of intron-22 inversion and PCR-SSP, PCR-SSO for genotyping of @entity17374 , @entity1533 , @entity3098 alleles and also for cytokine polymorphisms of @entity310 , @entity2533 , @entity688 , @entity650 and @entity379 . Chi-squared test and Fischer's exact test were used for statistical analysis. A total of 28 @entity1 had developed inhibitors (Group I), 71.4% high responding, while 24 had not (Group II). No statistically increased intron-22 inversion prevalence was found in Group I compared with Group II (P = 0.5). Comparison of HLA allele frequencies between the two groups showed statistically significant differences in the following genotypes (i) promoting inhibitors development: @entity1533 *01(P = 0.014), @entity1533 *01:01(P = 0.011) and @entity3098 *05:01 (P = 0.005) and (ii) possibly protecting from inhibitors development: @entity1533 *11 (P = 0.011), @entity1533 *11:01 (P = 0.031), @entity3098 *03 (P = 0.004) and @entity3098 *03:01 (P = 0.014). Analysis of cytokines revealed a higher incidence of inhibitor detection only in homozygotes of the haplotypes ACC and ATA for @entity688 polymorphisms (P = 0.05). There is evidence that HLA alleles and cytokine polymorphisms play an important role in @entity2801 inh development. On the contrary, no statistically significant results were obtained for intron-22 inversion and its impact on @entity2801 inhibitors formation.

title: Impact of HLA alleles and cytokine polymorphisms on inhibitors development in XXXX with severe @entity447 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children']

entities_list: @entity447 :: ('MESH:D006467', 'Disease') :: ['haemophilia A', 'HA']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: UNASSIGNED: Actively proliferating @entity42804 + skin stem cells are found deep in the hair follicle (HF). These cells renew the HF and drive its expansion in anagen phase. Their long residence and continuous mitotic activity make them prime candidates to transform into @entity1489 -initiating cells. This was investigated by subjecting @entity42804 -EGFP-Ires-CreERT2/ @entity26760 -LacZ @entity19 (haired and hairless) to chemical and UV carcinogenic regimens. In the course of these regimens @entity42804 + cells (EGFP+) remained exclusively located in HFs, and in @entity45 of hairless skin. In haired @entity19 , progeny of @entity42804 + stem cells (LacZ+ after a pulse of @entity440 ) appeared in the interfollicular epidermis upon UV-induced sunburn and in @entity865 -induced @entity1373 . In hairless @entity19 the progeny remained located in @entity45 and in HF remnants. Progeny in hairless skin was only detected interfollicularly at a late stage, in between outgrowing @entity5 . @entity42804 + stem cells were absent in the ultimate @entity5 masses, and no @entity5 appeared to be a (clonal) expansion of @entity42804 + cells (52 @entity5 with @entity440 at the start of @entity105 , 42 @entity5 with @entity440 late during @entity5 outgrowth). In contrast to @entity22416 /K15+ quiescent bulge stem cells, actively proliferating @entity42804 + stem cells do therefore not appear to be @entity5 drivers in experimental @entity105 .

title: @entity42804 + stem cells and their progeny in @entity19 epidermis under regimens of exogenous @entity105 , and their absence in ensuing XXXX .

entities_list: @entity26760 :: ('p|SUB|R|26|R', 'ProteinMutation') :: ['R26R']

entities_list: @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen']

entities_list: @entity1489 :: ('MESH:D012878', 'Disease') :: ['skin tumor']

entities_list: @entity1373 :: ('MESH:D006965', 'Disease') :: ['hyperplasia']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity45 :: ('MESH:D010181', 'Disease') :: ['deep-seated cysts']

entities_list: @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis', 'skin carcinogenesis']

answer: @entity1489 :: (MESH:D012878,Disease) :: ['skin tumors']


abstract: In a previous study, we found that aggressive immunosuppressive therapy with continuous high-dose oral @entity134 and @entity786 combined with plasma exchanges for extracapillary crescentic @entity631 gave controversial results since, although disease activity was controlled, iatrogenic complications had led to @entity204 in some aged @entity1 . We then modified our therapeutic regimen, and we analyze here the evolution of 30 consecutive @entity1 who were admitted for biopsy-proven crescentic @entity631 between 1989 and 1991. The mean plasma @entity1011 level at admission was 393 +/- 59 mumol/L (range 70 to 1100), and 15 @entity1 had crescent formation in more than 50% of glomeruli on initial renal biopsy. Ten @entity1 did not receive any immunosuppressive treatment since they either had a normal renal function or they had @entity177 and no severe extrarenal manifestation. The 20 other @entity1 received initial @entity134 pulses 500 mg x3 (n = 17), low oral @entity134 treatment (n = 20), @entity786 pulses (n = 13), or oral @entity786 (n = 3). In 4 cases plasma exchanges were also used. As a whole, 10 @entity1 (33%) were discharged with a normal renal function, and 18 @entity1 (60%) had @entity177 , 7 of them requiring dialysis or transplantation; only 2 @entity1 died of @entity548 . No severe iatrogenic complication was observed. These results indicate that reduction in oral @entity134 dosage, @entity786 pulse therapy rather than continuous oral treatment, and plasma exchanges do not induce overimmunosuppression and iatrogenic complication. It can be safe, well tolerated, and as effective as a more intensive immunosuppressive regimen for the treatment of crescentic extracapillary @entity631 .

title: Methylprednisolone and @entity786 pulse therapy in crescentic XXXX : safety and effectiveness.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['pulmonary hemorrhage']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['terminal renal failure', 'chronic renal failure']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity631 :: ('MESH:D005921', 'Disease') :: ['glomerulonephritis']

answer: @entity631 :: (MESH:D005921,Disease) :: ['glomerulonephritis']


abstract: Although PCR analysis is a sensitive test for detection of @entity1082 ) in the cervix, the proportion of cases of @entity3799 missed, or the false-negative rate, has been unknown. We determined the accuracy of PCR analysis for HPV DNA as a predictor of HPV-related @entity75 in a cross-sectional study of sexually active @entity1 , aged 18 to 50 years, from the University of Michigan Family Medicine HPV study. Of 133 eligible @entity1 , 41 underwent colposcopy because of a positive result for HPV of the cervix by the PCR method and 92 underwent screening colposcopy with biopsy prior to knowing the HPV PCR results. Twenty-four of those screened were subsequently found to also be HPV DNA positive. In those found to be HPV positive, histological studies revealed the presence of @entity6205 or @entity3146 in 16 @entity1 (24.6%) and changes suggestive of @entity6205 in 5 (7.6%). No HPV-negative @entity1 had an abnormal biopsy or cytology report (P = 0. 000001). The false-negative rate (1 - sensitivity) for HPV PCR analysis for detection of the presence of a cervical @entity66 was 0% (95% confidence interval, 0 to 0.047), and the specificity was 60.7%. In summary, PCR analysis for HPV DNA had a very low false-negative rate for predicting @entity66 of the cervix in a community-based population. This supports the validity of using the absence of HPV at the cervix, as determined by PCR testing, as an inclusion criterion for @entity1 in control groups in studies dealing with low-grade @entity75 .

title: Low false-negative rate of PCR analysis for detecting XXXX -related @entity75 .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'woman', 'patients']

entities_list: @entity6205 :: ('MESH:D062688', 'Disease') :: ['condyloma']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['HPV-related lesion', 'HPV-related lesions']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['cervical lesions']

entities_list: @entity3799 :: ('MESH:D002575', 'Disease') :: ['cervical dysplasia']

entities_list: @entity1082 :: ('10566', 'Species') :: ['human papillomavirus (HPV']

entities_list: @entity3146 :: ('MESH:D018290', 'Disease') :: ['cervical intraepithelial neoplasia']

answer: @entity1082 :: (10566,Species) :: ['human papillomavirus']


abstract: BACKGROUND: @entity14 is one of the most common @entity5 in Taiwan, as in the other part of the world. Surgical intervention is the best treatment of choice, yet some @entity1 still developed distant @entity3 after primary lesions were controlled. Metastasectomy is reported to improve the survival. This retrospective study was carried out to evaluate the relationship between the prognostic factors of lung metastasectomy and @entity1 survival. METHODS: From 1981 to 2000, 68 @entity1 undergoing complete lung metastasectomy in our section were studied. The prognostic factors influencing survival were analyzed, and the survival analysis was made with Kaplan-Meier method and compared by log-rank test. RESULTS: There was no surgical mortality in our series. The 5-year survival was 36.1%. None of parameters such as age, sex, stage of primary @entity14 , surgical method, size, number of metastatic deposits and disease free interval showed to relate with the survival. CONCLUSIONS: We concluded that lung metastasectomy for @entity14 is safe and effective to improve the survival. Since there were no significant factors influencing the survival, there should be no absolute contraindication against resectable @entity358 after primary lesions were adequately controlled.

title: Pulmonary resection for metastases from XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary metastasis']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['Colorectal cancer', 'colorectal cancer']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal adenocarcinomas']


abstract: BACKGROUND: Enhanced synthesis of extracellular matrix proteins including @entity11504 ( @entity11504 ) is associated with the development of @entity1463 . In this context we studied @entity11504 synthesis by tubular epithelial cells in response to @entity2533 ( @entity2533 ) and platelet-derived growth factor (PDGF). METHODS: @entity11504 protein synthesis by @entity1 tubular epithelial cells in culture (TEC) was measured by biosynthetic labeling and ELISA. Splicing of @entity11504 was assessed by RT-PCR and by Northern blotting. RESULTS: Cultivated TEC synthesized and released @entity11504 , the majority of which was deposited as an unsoluble protein and a minor portion (10 to 15%) was released into the supernatant. @entity2533 and, to a lesser degree, PDGF, up-regulated @entity11504 synthesis. All three @entity11504 splice variants ( @entity3796 , @entity8946 , and IIICS) were produced. PDGF did not influence the splicing. @entity2533 preferentially up-regulated the @entity3796 splice variant, but had no effect on the splicing of the other domains. CONCLUSIONS: PDGF and @entity2533 both up-regulate @entity11504 synthesis of TEC. @entity2533 , but not PDGF, also changed the quality of the de novo synthesized @entity11504 , and thus has a different role in the development of @entity1463 .

title: Fibronectin synthesis by XXXX tubular epithelial cells in culture: effects of PDGF and @entity2533 on synthesis and splicing.

entities_list: @entity11504 :: ('MESH:C536826', 'Disease') :: ['fibronectin', 'FN']

entities_list: @entity1463 :: ('MESH:D012598', 'Disease') :: ['sclerosis']

entities_list: @entity2533 :: ('7040', 'Gene') :: ['TGF-beta', 'transforming growth factor-beta']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: BACKGROUND/AIMS: Gelatinase B is a matrix metalloproteinase involved in extracellular matrix (ECM) breakdown often associated with @entity2318 and other @entity74 . It was investigated whether gelatinase B is involved in the pathogenesis of ECM degradation associated with @entity2024 . METHODS: Conjunctival biopsy specimens obtained from six @entity1 with active @entity11738 , six @entity1 with active @entity5902 ( @entity5902 ), and seven control subjects were studied. Immunohistochemical techniques and a specific monoclonal antibody against @entity1 gelatinase B were used, and a monoclonal antibody against macrophage @entity469 to identify mononuclear cells with gelatinase B immunoreactivity. In addition, quantitative zymography was used to compare the activity of gelatinase B in conjunctival biopsy specimens from seven @entity1 with active @entity11738 and seven control subjects. RESULTS: Gelatinase B was detected by immunohistochemistry only in polymorphonuclear cells located in the vascular lumens in three normal conjunctival biopsy specimens. In all @entity11738 specimens and in five @entity5902 specimens, gelatinase B was localised in monocyte/macrophage cells, positive for the @entity469 marker, and in polymorphonuclear cells. The majority of the latter cell type was located in intravascular spaces. Compared with @entity5902 specimens, @entity11738 specimens showed significantly more immunoreactive gelatinase B monocyte/macrophage cells (52.3 (21.9) v 8.2 (6.4); p <0.001) and polymorphonuclear cells (23.2 (14.2) v 6.3 (5.4); p = 0. 013). Activated macrophages with giant cell morphology clearly stained with the gelatinase B specific monoclonal antibody were observed in @entity11738 specimens. Zymography revealed that gelatinase B levels in @entity11738 specimens were significantly higher than the levels found in normal conjunctiva (1739.6 (1078.3) v 609.3 (395.9) scanning units; p = 0.0127). CONCLUSIONS: The increased activity of gelatinase B and numbers of inflammatory cells containing gelatinase B in @entity11738 specimens suggest that this enzyme plays a part in the pathogenesis of conjunctival @entity2318 in @entity11738 .

title: Expression of gelatinase B in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['pathological disorders']

entities_list: @entity2024 :: ('MESH:D003231', 'Disease') :: ['trachomatous conjunctivitis']

entities_list: @entity5902 :: ('MESH:D003233', 'Disease') :: ['VKC', 'vernal keratoconjunctivitis']

answer: @entity2024 :: (MESH:D003231,Disease) :: ['trachomatous conjunctivitis']


abstract: UNASSIGNED: @entity1 with @entity1721 ( @entity1721 ) have poor survival and high recurrence rate, but lack a prognostic biomarker. Disabled-2 ( @entity20697 ) is a crucial @entity5 suppressor, but its roles in @entity1721 are uncertain. We investigated whether low @entity20697 expression in @entity1721 could lead into @entity5 progression and poor prognosis. Our results found @entity1 with low- @entity20697 expression @entity1721 had significantly larger @entity5 size, deeper @entity5 invasion depth, lymph node @entity3 , worse survival, and higher recurrence rate (P<0.05). The Cox-regression model revealed low- @entity20697 expression was an independent factor of poor survival (P<0.05), and also of @entity5 recurrence with the predictive performance superior to clinical TNM stage (P<0.05). Low- @entity20697 @entity5 cells, validated by @entity20697 knockdown or over-expression, had higher phosphorylated @entity3963 and migration abilities, which could be suppressed by @entity3963 inhibitor treatment. @entity2533 -induced epithelial-to-mesenchymal transition (EMT) only existed in the high- @entity20697 cells, and related to worse prognosis of high- @entity20697 @entity1721 (P<0.05). In conclusion, @entity20697 can suppress the @entity3963 signaling, but correlate to have @entity2533 -induced EMT in @entity1721 . @entity20697 expression could be a biomarker to identify @entity1 with worse survival and high recurrence. Our data suggest @entity20697 expression can stratify @entity1 in need of aggressive surveillance and with possible benefit from anti- @entity3963 or anti- @entity2533 therapies.

title: Low disabled-2 expression promotes XXXX progression and determines poor survival and high recurrence of @entity1721 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity1721 :: ('MESH:C562729', 'Disease') :: ['esophageal squamous cell carcinomas', 'ESCCs']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor']


abstract: Delayed @entity9991 (DHTR) is one of the most feared complications of @entity3458 ( @entity3458 ). We retrospectively analyzed the clinical and biological features, treatments and outcomes of 99 DHTRs occurring in 69 referral center @entity1 over 12 years. The first clinical signs appeared a median of 9.4 [IQR, 3-22] days after the triggering transfusion (TT). The most frequent DHTR-related clinical manifestation was dark urine/ @entity8763 (94%). Most @entity1 (89%) had a painful @entity432 and 50% developed a secondary @entity5837 ( @entity5837 ). The median [IQR] hemoglobin-concentration nadir was 5.5 [4.5-6.3] g/dL and LDH peak was 1335 [798-2086] IU/L. Overall mortality was 6%. None of the @entity1 had been receiving chronic transfusions. Among these DHTRs, 61% were developed in previously immunized @entity1 , 28% in @entity1 with prior DHTR. Among Abs detected after the TT in 62% of the episodes, half are classically considered potentially harmful. No association could be established between clinical severity and immunohematological profile and/or the type and specificity of Abs detected after the TT. Management consisted of supportive care alone (53%) or with adjunctive measures (47%), including recombinant @entity1307 and sometimes rituximab and/or immunosuppressants. Additional transfusions were either ineffective or worsened @entity2142 . In some cases, severe @entity2142 can be likely responsible for the vascular reaction and high rates of @entity5837 , @entity120 and (multi)organ failure. In conclusion, clinicians and @entity1 must recognize early DHTR signs to avoid additional transfusions. For @entity1 with a history of RBC immunization or DHTR, transfusion indications should be restricted. Am. J. Hematol. 91:989-994, 2016.    2016 Wiley Periodicals, Inc.

title: Delayed @entity9991 in adult XXXX : presentations, outcomes, and treatments of 99 referral center episodes.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity8763 :: ('MESH:D006456', 'Disease') :: ['hemoglobinuria']

entities_list: @entity3458 :: ('MESH:D000755', 'Disease') :: ['SCD', 'sickle-cell disease']

entities_list: @entity1307 :: ('2056', 'Gene') :: ['erythropoietin']

entities_list: @entity5837 :: ('MESH:D056586', 'Disease') :: ['acute chest syndrome', 'ACS']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension']

entities_list: @entity9991 :: ('MESH:D065227', 'Disease') :: ['hemolytic transfusion reaction']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['vaso-occlusive crisis']

entities_list: @entity2142 :: ('MESH:D006461', 'Disease') :: ['hemolysis', 'intravascular hemolysis']

answer: @entity3458 :: (MESH:D000755,Disease) :: ['sickle-cell disease']


abstract: PURPOSE: The long-term survival of @entity1 with completely resected stage I @entity1149 ( @entity1149 ) is not optimal because of undetected lymph node @entity3944 at the time of surgery. The aim of this study is to evaluate the role of survivin and @entity22769 mRNA expression in histopathologically negative lymph nodes of stage I @entity1149 @entity1 as markers of @entity3944 . METHODS: Clinical data and tissue samples of primary @entity5 and lymph nodes were collected from 44 @entity1 with stage I @entity1149 . Reverse-transcriptase-PCR (RT-PCR) was used to detect survivin and @entity22769 mRNA expression in these @entity5 and lymph node samples. RESULTS: Survivin mRNA was detected in all @entity5 , and @entity22769 mRNA was detectable in 39 of the 44 @entity5 . The cut-off values of survivin and @entity22769 mRNA levels for diagnosing @entity3944 in lymph nodes were set up according to the expression of survivin and @entity22769 mRNA in control lymph nodes. Fifteen (34.1 %) of 44 stage I NSCCL @entity1 had @entity3944 in lymph nodes by survivin and/or @entity22769 mRNA positive expression. Survival analysis showed higher rate of @entity5 recurrences and @entity5 -related @entity204 in @entity1 with lymph node @entity3944 (P < 0.001 and P = 0.001, respectively). Tumor-free survival and overall survival were significantly worse in @entity1 with lymph node @entity3944 compared with those without such @entity3944 (P = 0.007 and P = 0.01, respectively). CONCLUSION: RT-RCR assay for survivin and @entity22769 mRNA can be considered as useful diagnostic tool for the detection of lymph node @entity3944 for stage I @entity1149 @entity1 .

title: Gene diagnosis of micrometastases in regional lymph nodes of @entity1 with stage I XXXX : impact on staging and prognosis.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumors', 'cancer', 'tumors']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity3944 :: ('MESH:D061206', 'Disease') :: ['micrometastasis']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']


abstract: OBJECTIVE: To study the characteristics of occurrence of postinfarction @entity9009 ( @entity9009 ) and preliminarily evaluate the proper timing of operation and its effect. METHODS: Twenty @entity1 with postinfarction @entity9009 were divided into two groups: surgical repair (14 @entity1 ), and conventional treatment (6 @entity1 ). Clinical data were analyzed and the 14 @entity1 were followed up for 4 months-14 years. RESULTS: The 6 @entity1 died within 6 hours-7 days. Of the 14 @entity1 treated surgically, however, 4 had their @entity397 closed by the technique of plication and the rest by prosthetic patches. Concomitant procedures included resection of postinfarction @entity439 in all 14 @entity1 and coronary artery grafting bypass in 3. Five @entity1 (35.7%) died during peri-operation, and 14.3% had residual @entity1757 . 2 @entity1 died of @entity712 7 and 9 years after the operation respectively, 1 was lost to follow-up, and the rest were in good condition. CONCLUSIONS: The proper timing of operation determined by the cardiac function of @entity1 . It is necessary to improve condition of circulation before operation. The mortality rate of emergency operation is high within 3 days after @entity9009 , and residual @entity9009 tends to develop in a week after the repair. Operation should be performed a week after @entity9009 . The early operative mortality is closely related to preoperative @entity260 .

title: [Surgical repair of postinfarction XXXX ].

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity9009 :: ('MESH:D018658', 'Disease') :: ['VSR', 'ventricular septal rupture']

entities_list: @entity1757 :: ('MESH:D006345', 'Disease') :: ['ventricular septal defects']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['cardiogenic shock and postoperative complications']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['ruptures']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['ventricular aneurysm']

answer: @entity9009 :: (MESH:D018658,Disease) :: ['ventricular septal rupture']


abstract: Management responses to prion diseases of @entity291 , deer, and @entity2498 create a significant need for safe and effective disposal of infected carcasses and other materials. Furthermore, soil may contribute to the horizontal transmission of @entity742 scrapie and cervid chronic wasting disease by serving as an environmental reservoirforthe infectious agent. As an initial step toward understanding prion mobility in porous materials such as soil and landfilled waste, the influence of pH and ionic strength (l) on pathogenic @entity47822 (PrPsc) properties (viz. aggregation state and zeta-potential) and adsorption to quartz sand was investigated. The apparent average isoelectric point of PrPsc aggregates was 4.6. PrPsc aggregate size was largest between pH 4 and 6, and increased with increasing l at pH 7. Adsorption to quartz sand was maximal near the apparent isoelectric point of PrPsc aggregates and decreased as pH either declined or increased. PrPsc adsorption increased as suspension l increased, and reached an apparent plateau at l approximately 0.1 M. While trends with pH and l in PrPsc attachment to quartz surfaces were consistent with predictions based on Born-DLVO theory, non-DLVO forces appeared to contribute to adsorption at pH 7 and 9 (l = 10 mM). Our findings suggest that disposal strategies that elevate pH (e.g., burial in lime or @entity238 ash), may increase PrPsc mobility. Similarly, PrPsc mobility may increase as a landfill ages, due to increases in pH and decreases in l of the leachate.

title: Adsorption of pathogenic XXXX to quartz sand.

answer: @entity47822 :: (281427(Tax:9913),Gene) :: ['prion protein']


abstract: OBJECTIVES: The objective of this work was to study the reporting of resected @entity694 and to compare them with Consensus Guidelines published in January 1998. METHODS: The study included 535 @entity694 collected in 8 French registries in 1995, and chosen by drawing lots. For each report, the presence of the information requested by the Guidelines was looked for. Three synthetic variables were built: 2 scores and one qualitative at 2 classes. The influence of @entity1 , @entity5 and health care system's characteristics was analysed on the 3 dependent variables. RESULTS: Some important variations were observed for information's percents in reporting. In monovariate analysis, scores were significantly influenced by @entity5 's sub-location, area of @entity1 's residence, surgical center, type of laboratories and pathologist case volume. In multivariate analysis, significant heterogeneity in practices remained between geographical areas. Types of laboratories and pathologist case volume affected differently dependent variables. CONCLUSION: This study shows the necessity to assess the practices before consensus because of the impact of pathological forms in therapeutic decisions and variations observed.

title: [Reporting of resected XXXX . Assessment of practices in 8 French counties in 1995].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colonic carcinomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumour']

answer: @entity694 :: (MESH:D003110,Disease) :: ['colonic carcinomas']


abstract: One hundred and eighty strains of @entity328 were isolated from various materials at the Institute of Medical Microbiology in Zurich between March and October 1978. Examination of these isolates for resistance to 6 standard antimicrobials revealed that 17 (9.4%) strains were resistant to the @entity2930 , 2 strains to @entity207 / @entity206 and 1 strain to both @entity803 and @entity2755 . All strains were highly sensitive to @entity3397 , @entity5821 and @entity2929 . Serotyping of the pneumococci was done by the capsular quellung reaction. The prevalent serotypes in the entire collection of strains were Nos. 6, 23, 19, 3, 9, 14 and 7. The prevalent serotypes of strains isolated from blood, cerebrospinal fluid, pus, and bronchial secretions were Nos. 4, 8, 7, 14, 9, 3, 19 and 6. Vaccination with PneumovaxTM, a vaccine containing 14 capsular antigens, should provide protection against 75% of pneumococci identified as true pathogens in this study. Pneumococci are rather rarely isolated in our laboratories. For this reason, and because the strains isolated are still sensitive to antibiotics in conventional use, mass vaccination of the population in Switzerland is not recommended. Vaccination should be carried out in certain high risk groups of @entity1 .

title: [Antimicrobial resistance and serotypes of XXXX in Switzerland].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2930 :: ('MESH:D013754', 'Chemical') :: ['tetracyclines']

entities_list: @entity2929 :: ('MESH:D004917', 'Chemical') :: ['erythromycin']

entities_list: @entity5821 :: ('MESH:D002512', 'Chemical') :: ['cephalothin']

entities_list: @entity2755 :: ('MESH:D002701', 'Chemical') :: ['chloramphenicol']

entities_list: @entity3397 :: ('MESH:D010400', 'Chemical') :: ['benzylpenicillin']

entities_list: @entity207 :: ('MESH:D013420', 'Chemical') :: ['sulphamethoxazole']

entities_list: @entity803 :: ('MESH:D013752', 'Chemical') :: ['tetracycline']

entities_list: @entity328 :: ('1313', 'Species') :: ['Streptococcus pneumoniae']

entities_list: @entity206 :: ('MESH:D014295', 'Chemical') :: ['trimethoprim']

answer: @entity328 :: (1313,Species) :: ['Streptococcus pneumoniae']


abstract: PURPOSE/OBJECTIVES: To determine the reliability of the Index of @entity390 , Vomiting, and Retching (INVR), a new format of the Rhodes Index of @entity1209 Form 2 (INV-2). DESIGN AND SETTING: A parallel form study was conducted at a large, Midwestern teaching hospital and a @entity5 center. SAMPLE: Convenience sample of 159 subjects: 40 obstetrical, 60 oncological, 59 medical/surgical. METHODS: Two instruments, the INVR and the INV-2, were administered approximately 30-60 minutes apart. One-half of the subjects completed the INVR first, and the other half completed the INV-2 first. MAIN OUTCOME MEASURES: Equivalency measures of reliability correlation coefficients for both instruments. FINDINGS: A high rate of agreement was found in the responses between the two forms. In cases of @entity16488 , the responses to the INVR were more frequently consistent than the responses to the original form. CONCLUSIONS: INVR has tested reliability and is more user friendly for the @entity1 and the healthcare provider. IMPLICATIONS FOR NURSING PRACTICE: Nurses have a focal role in managing symptoms. Managing @entity390 , @entity391 , and retching requires excellent assessment skills of the @entity1 's personal symptom experience and knowledge of pharmacology. Efficient, cost-saving assessments require accurate self-report instruments that permit @entity1 to quantify their symptom experiences. The INVR can provide a scientific base from which to prescribe and teach @entity1 and may improve their quality of life. Reliable and valid self-reporting instruments are essential for managing these adverse symptoms.

title: The Index of XXXX , Vomiting, and Retching: a new format of the lndex of @entity1209 .

entities_list: @entity16488 :: ('MESH:D018262', 'Disease') :: ['clear disagreement']

entities_list: @entity390 :: ('MESH:D009325', 'Disease') :: ['Nausea', 'nausea']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity1209 :: ('MESH:D020250', 'Disease') :: ['Nausea and Vomiting']

answer: @entity390 :: (MESH:D009325,Disease) :: ['Nausea']


abstract: @entity43 relapse is often characterized by metastatic spread throughout the peritoneal cavity with @entity5 attached to multiple organs. In this study, interaction of @entity43 cells with the peritoneal @entity5 microenvironment was evaluated in a xenograft model based on intraperitoneal injection of fluorescent SKOV3.ip1 @entity43 cells. Intra-vital microscopy of mixed GFP-red fluorescent protein (RFP) cell populations injected into the peritoneum demonstrated that @entity5 cells aggregate and attach as mixed spheroids, emphasizing the importance of homotypic adhesion in @entity5 formation. Electron microscopy provided high resolution structural information about local attachment sites. Experimental measurements from the @entity19 model were used to build a three-dimensional cellular Potts @entity43 model (OvTM) that examines @entity43 cell attachment, @entity6722 , growth, and vascularization. OvTM simulations provide insight into the relative influence of @entity5 cell-cell adhesion, @entity26 availability, and local architecture on @entity5 growth and morphology. Notably, @entity5 on the mesentery, omentum, or spleen readily invade the "open" architecture, while @entity5 attached to the gut encounter barriers that restrict invasion and instead rapidly expand into the peritoneal space. Simulations suggest that rapid neovascularization of SKOV3.ip1 @entity5 is triggered by constitutive release of angiogenic factors in the absence of @entity519 . This research highlights the importance of cellular adhesion and @entity5 microenvironment in the seeding of secondary @entity43 on diverse organs within the peritoneal cavity. Results of the OvTM simulations indicate that invasion is strongly influenced by features underlying the mesothelial lining at different sites, but is also affected by local production of chemotactic factors. The integrated in vivo @entity19 model and computer simulations provide a unique platform for evaluating targeted therapies for @entity43 relapse.

title: XXXX attachment, invasion, and vascularization reflect unique microenvironments in the peritoneum: insights from xenograft and mathematical models.

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian tumors', 'ovarian tumor', 'ovarian cancer', 'Ovarian cancer']

entities_list: @entity6722 :: ('MESH:C565534', 'Disease') :: ['chemotaxis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'tumors']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

answer: @entity43 :: (MESH:D010051,Disease) :: ['Ovarian tumor']


abstract: OBJECTIVES: To evaluate the frequency of skin colonization by Fusarium spp. in high-risk hematologic @entity1 and its impact on the subsequent development of @entity3 . METHODS: We screened all high-risk hematologic @entity1 from August 2008 to December 2009 with cultures of 6 pre-defined areas in the feet and hands on admission and at discharge. In addition, cultures of any @entity272 present on admission were performed. RESULTS: Among 61 @entity1 screened, alterations in the skin and/or nails were present in 32 @entity1 (52%) on admission, mostly represented by abnormal appearing nails and intertrigo. Four @entity1 (7.2%) presented positive baseline cultures for Fusarium spp., all in existing lesions of @entity6313 , intertrigo or both. Invasive @entity22214 was diagnosed in six @entity1 . The presence of a @entity272 at baseline that grew Fusarium spp. was associated with the subsequent development of @entity3 (p  =  0.04). CONCLUSIONS: Our data suggest that: 1) baseline cultures in @entity1 without alterations in the skin and/or nails seems not justifiable; 2) cultures of pre-existing lesions may help to identify a group of @entity1 at higher risk to develop @entity3 . The use of anti-mould prophylaxis in this setting should be explored in future studies.

title: Superficial XXXX positive for Fusarium are associated with subsequent development of @entity3 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6313 :: ('MESH:D014009', 'Disease') :: ['onychomycosis']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['skin lesion']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['invasive fusariosis']

entities_list: @entity22214 :: ('MESH:D060585', 'Disease') :: ['fusariosis']

answer: @entity272 :: (MESH:D012871,Disease) :: ['skin lesions']


abstract: BACKGROUND: Very rapid @entity604 , @entity2331 and skeletal morbidity after renal transplantation have been well documented and found to occur in a sex dependent fashion. Glucocorticoids, @entity205 and pre-existing @entity1381 have been implicated in the pathogenesis of the skeletal lesions. Glucocorticoid induced @entity2331 is also a serious clinical problem in @entity1 with various nonrenal diseases and can be prevented, or at least attenuated, by @entity5279 and other @entity171 . METHOD: We prospectively studied 26 male @entity1 undergoing renal transplantation, and randomized them to receive either placebo or intravenous @entity5279 (0.5 mg/kg) at the time of transplantation and again one month later. All @entity1 received immunosuppression comprising @entity617 , @entity205 and @entity500 . The bone mineral density (BMD) of the second, third and fourth lumbar vertebrae and of the femoral neck was measured at the time of transplantation and at three months and 12 months after transplantation using dual energy X-ray absorptiometry (DXA). RESULTS: Twelve months after transplantation, the mean (+/- SEM) BMD of the lumbar vertebrae in @entity1 who received placebo had decreased 6.4% (P < 0.05). In contrast, @entity1 who received @entity5279 experienced no significant reduction of BMD at the lumbar vertebrae. At the femoral neck, placebo-treated @entity1 showed a reduction of BMD of 9% (P < 0.005), whereas there was no significant change in the @entity5279 treated group. The two study groups had similar patient profiles, serum @entity461 ( @entity461 ) and @entity5715 concentrations. After transplantation, comparable falls in the serum @entity1011 and @entity461 concentration were found in the two groups. Apart from transient @entity3747 in two @entity1 , no significant adverse effects of @entity5279 were noted. CONCLUSION: This study has shown that the early rapid @entity604 that occurs in @entity1 during the first 12 months after renal transplantation can be prevented by two intravenous doses of @entity5279 given at transplantation and one month later. The regimen was simple to administer, well tolerated and potentially applicable to other clinical groups of glucocorticoid treatment @entity1 .

title: @entity5279 therapy as prevention of XXXX following renal transplantation.

entities_list: @entity1 :: ('9606', 'Species') :: ['men', 'patients']

entities_list: @entity3747 :: ('MESH:D006996', 'Disease') :: ['hypocalcemia']

entities_list: @entity5279 :: ('MESH:C019248', 'Chemical') :: ['pamidronate']

entities_list: @entity171 :: ('MESH:D004164', 'Chemical') :: ['bisphosphonates']

entities_list: @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine']

entities_list: @entity604 :: ('MESH:D016301', 'Disease') :: ['bone loss']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine']

entities_list: @entity2331 :: ('MESH:D001851', 'Disease') :: ['osteopenia']

entities_list: @entity1381 :: ('MESH:D006463', 'Disease') :: ['uremic osteodystrophy']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity5715 :: ('CHEBI:28984', 'Chemical') :: ['aluminium']

entities_list: @entity461 :: ('5741', 'Gene') :: ['PTH', 'parathyroid hormone']

entities_list: @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']

answer: @entity604 :: (MESH:D016301,Disease) :: ['bone loss']


abstract: @entity1534 and @entity2394 are two of the @entity2394 spp. that infect @entity1 . @entity1534 has been linked to significant gastric pathology. Coinfection with @entity2394 spp. may influence infectious burden, pathogenesis, and antibiotic resistance; however, this has not been studied. The aims of this study were to identify the incidence of @entity10331 and to analyze the effects of coinfection with both organisms on gastric pathology in a well-characterized South African population. Biopsy samples from the gastric corpora and antra of volunteers (n = 90) were subjected to histological examination and PCR for the identification of @entity1534 and @entity10331 . We further investigated the effect of global strain type on the occurrence of precursor lesions by assigning @entity377 sequences derived from PCR amplification of three genes to global groupings (ancestral Africa1, ancestral Africa2, ancestral Europe, ancestral Asia, and mixed). @entity1534 was detected in 75 (83.3%), @entity10331 in 23 (25.6%), and coinfection in 21 (23.3%) of the volunteers by PCR. @entity10331 was randomly distributed among adults and @entity1 but clustered within families, suggesting intrafamilial transmission. Analysis of histopathology scores revealed no differences in @entity194 , activity, and @entity2394 density between @entity10331 -positive and @entity10331 -negative volunteers. @entity1534 substrains common to southern Africa showed no differences in @entity32 or @entity194 scores. The incidences of @entity10331 and coinfection with @entity1534 in the African population are high. @entity10331 infection, however, does not influence specific gastric pathology in this population.

title: Incidence of @entity2394 and the effect of coinfection with XXXX on the gastric mucosa in the African population.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'humans']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity377 :: ('CHEBI:36976', 'Chemical') :: ['nucleotide']

entities_list: @entity1534 :: ('210', 'Species') :: ['H. pylori', 'Helicobacter pylori']

entities_list: @entity2394 :: ('214', 'Species') :: ['Helicobacter', 'helicobacter', 'Helicobacter felis']

answer: @entity1534 :: (210,Species) :: ['Helicobacter pylori']


abstract: The role of @entity32 in childhood @entity565 is not well defined, despite modern treatment approaches recommending potent anti-inflammatory therapy for an increasing number of @entity1 . In this study, induced sputum analysis was used to investigate the relationships among sputum inflammatory cells (eosinophils and mast cells), @entity565 symptoms, and @entity1224 to @entity4372 saline in a cohort of 170 @entity1 aged 8-14 years. @entity1 who reported @entity565 symptoms in the past 2 wk had a 2. 25-fold (95% to CI, 1.20-4.24) increased odds of having significant sputum @entity1712 . Hyperresponsiveness to @entity4372 saline was strongly associated with higher levels of sputum eosinophils ([OR] 4. 36, 1.70-11.20), sputum mast cells (OR 7.46, 2.48-22.75), and nasal eosinophils (OR 4.73, 1.89-11.86). Interestingly, @entity1 were more likely than @entity1 to have features of @entity32 (sputum mast cells, OR 3.33, 1.15-9.65; nasal eosinophils, OR 3.25, 1.72-5. 97), which is consistent with the known increase in @entity565 prevalence in @entity1 in this age group. Airway @entity32 with eosinophils and mast cells is likely to be important in the pathogenesis of @entity565 in childhood. Induced sputum analysis can be used to evaluate this problem and has the potential to be a useful tool for monitoring therapy.

title: Epidemiological association of @entity32 with XXXX symptoms and @entity1224 in childhood.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Children', 'girls', 'boys']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'airway inflammation']

entities_list: @entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophilia']

entities_list: @entity4372 :: ('MESH:D009122', 'Disease') :: ['hypertonic']

entities_list: @entity1224 :: ('MESH:D000402', 'Disease') :: ['airway hyperresponsiveness']

answer: @entity565 :: (MESH:D001249,Disease) :: ['asthma']


abstract: PURPOSE: To evaluate the feasibility and usefulness of extracorporeal lithotripsy endoscopically controlled by simultaneous flexible ureterorenoscopy (LECURS) and combined with @entity23008 laser lithotripsy for @entity1290 surgery. METHODS: Retrograde flexible ureteroscopy allowed stone visualization and intrarenal relocation when possible. Extracorporeal schock wave lithotripsy (ESWL) was performed under direct vision allowing constant focal zone adjustment for optimal stone fragmentation. Holmium laser lithotripsy was used simultaneously when necessary. Post-operative assessment included ultrasound at day one and abdominal CT scan 3 weeks later to evaluate for residual fragments. RESULTS: Six @entity1 with @entity1290 were recruited including 3 with relative contraindication to ESWL. One @entity1 had a stone beyond an infundibular stenosis and 2 had multiple stones in a horseshoe kidney with an uretero-pelvic junction (UPJ) stricture. A 100 % stone fragmentation rate was obtained. Post-operative ultrasound was normal in 5 @entity1 and showed slight peri-renal infiltration in the other. One @entity1 developed an obstructive @entity2885 requiring antibiotics and changing a double J to a ureteral catheter. No other complications were noted. Three @entity1 (50 %) were stone free after LECURS. Three @entity1 underwent a second-look procedure for small (<3 mm) retained residual fragments. No damage was seen with the digital ureteroscopes, laser fibers or stone baskets. CONCLUSIONS: This initial experience with LECURS has shown to be feasible and safe. This opens the opportunity for further evaluation of this approach in order to improve outcomes of both approaches.

title: Extracorporeal lithotripsy endoscopically controlled by ureterorenoscopy (LECURS): a new concept for the treatment of XXXX -first clinical experience using digital ureterorenoscopes.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1290 :: ('MESH:D007669', 'Disease') :: ['kidney stones']

entities_list: @entity2885 :: ('MESH:D011704', 'Disease') :: ['pyelonephritis']

answer: @entity1290 :: (MESH:D007669,Disease) :: ['kidney stones']


abstract: OBJECTIVES: To estimate the health service use over 9 years after the injury year for @entity1 with @entity131 ( @entity131 ), @entity1566 ( @entity1566 ) and @entity174 ( @entity174 ), and compare with non-injured. DESIGN: A register-based cohort design with a 9-year follow-up period. SETTING: The Danish population. @entity1 : The study included 434, 100 and 278 hospital-treated incident @entity1 with @entity131 , @entity1566 and @entity174 , respectively, among 20-year-olds to 64-year-olds identified using the National @entity1 Register. Controls for each @entity1 group were drawn from the population register, matched by age, sex and health service use during 1995. All were followed during 1996-2005 by linkage to national health registers. The observations were excluded when the @entity1 left Denmark or died. OUTCOME MEASURES: The use of hospital treatments, contacts with general practitioners and the use of physiotherapy. RESULTS: Compared to the controls, more @entity1 with @entity131 and @entity1566 were hospital admitted all 9 years after the injury year, on average 0.36 and 0.50 times annually, respectively. For @entity1 with @entity174 hospital admissions returned to baseline year 2 after the injury year. For @entity1 with @entity1566 the use of general practitioner services remained at an increased level year 9 after the injury year, while it returned to baseline level year 4 after the injury year for @entity1 with @entity131 and year 2 for @entity1 with @entity174 . For @entity1 with @entity1566 physiotherapy use remained increased over 9 years after the injury year, while it returned to baseline the fifth year for @entity1 with @entity131 and the third year after for @entity1 with @entity174 . CONCLUSIONS: @entity131 and @entity1566 increase the use of health services over 9 years after the injury year, while most health service use after @entity174 returned to baseline 2 years after the injury year.

title: Health service use in adults 20-64 years with @entity131 , @entity1566 or XXXX . A cohort study with 9-year follow-up.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient', 'PARTICIPANTS']

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['TBI', 'traumatic brain injury']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['PF', 'pelvic fracture']

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injury', 'SCI']

answer: @entity174 :: (MESH:D050723,Disease) :: ['pelvic fracture']


abstract: PURPOSE/OBJECTIVES: To evaluate the effects of a rehabilitation program on quality of life, @entity1295 , fear of movement (kinesiophobia), distress, @entity148 , @entity308 , and physical condition. DESIGN: Pretest/post-test. SETTING: An outpatient rehabilitation setting in the Oncology Centre at the University Hospital Brussels in Belgium. SAMPLE: 36 @entity1 who had completed @entity5 treatment with a curative potential. METHODS: @entity1 completed a questionnaire and underwent a physical test at baseline and at the end of the program. The measurement instruments used included the European Organisation for Research and Treatment of @entity5 Quality-of-Life Questionnaire-Core 30, Functional Assessment of @entity5 Therapy-Fatigue, Hospital Anxiety and @entity308 Scale, RAND-36, Tampa Scale for Kinesiophobia, Distress Barometer, and Tecumseh Step Test. MAIN RESEARCH VARIABLES: Quality of life, @entity1295 , kinesiophobia, distress, @entity148 , @entity308 , and physical condition. FINDINGS: Significant improvement was observed in quality of life (p < 0.001), physical condition (p = 0.007), @entity1295 (p = 0.01), and @entity308 (p = 0.012). In contrast, kinesiophobia (p = 0.229), distress (p = 0.344), and @entity148 (p = 0.101) did not change significantly. CONCLUSIONS: A general and significant improvement in all aspects affecting quality of life and rehabilitation was observed, but less so for aspects that might be influenced by prognostic concerns. The relative contribution of the program versus spontaneous recovery and long-term impact need to be determined further in a prospective randomized study. IMPLICATIONS FOR NURSING: Multidisciplinary rehabilitation should become part of the total care plan for @entity1 with @entity5 .

title: Evaluation of a comprehensive rehabilitation program for post-treatment @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Participants']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depression']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Cancer']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: OBJECTIVE: To test the hypothesis that @entity1 with @entity309 ( @entity309 ) have clinical or subclinical evidence of @entity1897 or @entity121 . METHODS: We studied 40 seropositive @entity1 with @entity309 , mean age 46.6 years (SD 6.4), and 56 healthy controls, mean age 43.0 years (SD 9.1). @entity1 had a mean disease duration of 13.0 years (SD 7.8). We performed electromyographic examination of 4 muscles [extensor digitorum communis (EDC), biceps brachii (BB), vastus lateralis (VL), and tibialis anterior (TA)] on the right side in both groups. Quantitative data included percentage of polyphasic potentials, motor unit potential amplitude, area, duration, turns, and number of polyphasic potentials. RESULTS: There were statistically significantly higher proportions of polyphasic potentials in 3 muscles in @entity1 compared with controls. Mean number of phases in EDC was 4.6 (SD 0.4) in the @entity1 and 4.1 (0.5) in controls (p = 0.0001). The values for the VL were 4.1 (SD 0.4) in @entity1 compared with 3.6 (0.4) in controls (p = 0.0001), and in the TA 4.5 (SD 0.5) versus 4.0 (0.4) (p = 0.0001). We also found significantly increased duration of motor unit potentials in the VL and TA of @entity1 . The amplitudes of motor unit action potentials were not significantly different in the 2 groups. CONCLUSION: The study reveals an increased prevalence of neurogenic but not myogenic changes in @entity1 with @entity309 compared with controls.

title: @entity121 and neuropathy in XXXX . A quantitative controlled electromyographic study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients']

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral neuropathy']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['myopathy']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

answer: @entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']


abstract: Loma salmonae is a common gill parasite of salmonids, and essentially all species in the genus @entity11806 are susceptible. Infections occur in both fresh and salt water. Loma salmonae is directly transmissible by ingestion of spores or infected tissue. The parasite infects the wall of blood vessels of various organs, but the gill is the primary site of @entity281 . Initial @entity281 occurs in the intestine, and xenomas are easily detected in the gills by standard histology at 4-6 wk post-exposure. A few presporogonic stages of the parasite are found in the heart endothelium prior to xenoma formation in the gills. Ultrastructure studies of early infections demonstrated that wandering blood cells transport the meronts to the gills, and that merogony occurs in pillar cells and other cells underlying the gill endothelium. Xenomas develop in these cells, resulting in hypertrophied host cells filled with spores. Xenomas @entity397 , and are associated with severe @entity32 in which free spores are found in macrophages. The parasites are most pathogenic during this phase of the @entity281 , resulting in severe @entity1333 and clinical disease. Both @entity5660 ( @entity5660 ) and @entity11806 ( @entity11806 ishawytscha) recover from infections, but free spores persist in kidney and spleen phagocytes for many months after xenomas are absent in @entity11806 . Fish that have recovered from the @entity281 show strong immunity against the parasite, lasting up to 1 year. Fish are susceptible to @entity281 by other routes of exposure by spores; co-habitation, anal gavage, and intramuscular, intraperitoneal and intravascular injection. Autoinfection probably occurs following release of spores in blood vessels after @entity397 . The optimal temperature for L. salmonae infections is 15-17 degrees C, with a permissive range of 11-20 degrees C.

title: Review of the sequential development of Loma salmonae (Microsporidia) based on experimental infections of @entity5660 ( @entity5660 ) and @entity11806 ( XXXX ).

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity5660 :: ('8022', 'Species') :: ['Oncorhynchus mykiss', 'rainbow trout']

entities_list: @entity11806 :: ('74940', 'Species') :: ['Chinook salmon', 'Oncorhynchus']

entities_list: @entity1333 :: ('MESH:D014657', 'Disease') :: ['vasculitis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['xenomas rupture', 'ultimately rupture']

answer: @entity11806 :: (74940,Species) :: ['O. tshawytscha']


abstract: Injection of @entity1068 in high concentrations into tissues produces @entity39 . The benefits of direct injection of 98% @entity1068 into hepatic @entity3 from @entity8708 ( @entity18399 )-induced @entity694 was investigated in groups of 20 @entity35 of either sex. At 10 weeks of age, @entity35 were subcutaneously injected every week with 10 mg/kg DMH for 28 weeks. They were then housed for 3 months. At the end of this period all the animals had developed @entity694 with multiple hepatic @entity3 . Total colectomy and the fashioning of an ileostomy coupled with direct injection of 0.1-0.2 ml of @entity1068 into each of the hepatic @entity3 , after mobilizing the liver by dividing its fascial attachments to facilitate easier @entity5 detection by inspection and palpation, afforded a significant survival advantage relative to colectomy alone (20.1 +/- 0.2 months of age, vs, 12.8 +/- 0.2 months of age, mean +/- SEM, n = 20, p < 0.01 by the Mann-Whitney U test). The clinical implications of these observations were, therefore, examined in a pilot study carried out on 6 @entity1 (2 @entity1 and 4 @entity1 with an age range of 43-71 years, mean 56) who had @entity420 of the sigmoid colon with multiple hepatic secondaries. The @entity5 was resected and an end-to-end @entity254 effected, then all palpable hepatic @entity3 were slowly injected with 1-1.5 ml of 98% @entity1068 . Two weeks post-operatively and thereafter once every 2 months any hepatic lesions detected ultrasonically were similarly treated percutaneously. This treatment produced no adverse effects of any significance. None of the @entity1 died during the first post-operative year. @entity204 was due to disease spread in all the @entity1 . The mean survival measured from the time of @entity5 resection until death from any cause was 20 months (range 17-26 months). It thus appears that chemonecrosis for the treatment of liver @entity3 from @entity694 is a simple and safe therapeutic modality which offers a survival gain.

title: Chemonecrosis for localized dynamic destruction of hepatic @entity3 of XXXX . A new approach.

entities_list: @entity1 :: ('9606', 'Species') :: ['men', 'women', 'patients']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['coagulative necrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour', 'colonic tumour']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

entities_list: @entity8708 :: ('MESH:D019813', 'Chemical') :: ['1,2-dimethylhydrazine']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats', 'rats']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colonic cancer', 'colonic carcinoma']

entities_list: @entity1068 :: ('MESH:D000431', 'Chemical') :: ['ethyl alcohol', 'ethanol']

answer: @entity694 :: (MESH:D003110,Disease) :: ['colonic cancer']


abstract: The objective of our study was to determine the frequency of @entity470 -gene rearrangement in relation to @entity5 -growth behaviour in an unselected group of @entity11 @entity1 . We investigated 73 @entity5 with different grades of @entity5 (17 low-grade @entity11 , 14 anaplastic variants, and 42 @entity11 ) by Southern analysis, reverse transcriptase PCR (RT-PCR) amplification of mRNA, and Western analysis. An amplification of the @entity470 gene was present in 19/42 @entity11 but in only 1 anaplastic @entity816 . By RT-PCR, 4/19 @entity11 with gene amplification showed a specific @entity1472 -terminal aberrant splice mutation of 801 bp in addition to undeleted mRNA. By Western analysis, 27/42 @entity11 showed expression of the @entity470 protein. Protein levels, however, varied among individual @entity5 . Four @entity11 containing an aberrant splice mutation exhibited an immunoreactive protein of 130 kDa MW in addition to the normal @entity470 protein p170. All @entity11 @entity1 underwent surgery followed by a standard course of radiotherapy. Neuroradiological follow-up in 31/42 @entity11 @entity1 consisted of bimonthly MRI examinations. There was a statistically significant difference in the mean latency period until @entity5 regrowth of @entity1 suffering from @entity11 with and without @entity470 -gene amplification (9 weeks vs. 32 weeks). Our data indicate more rapid @entity5 regrowth kinetics of @entity11 with amplified EGF receptor genes in vivo.

title: Amplification of the XXXX gene correlates with different growth behaviour in @entity1 glioblastoma.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['glial tumours', 'tumours', 'malignancy', 'tumour']

entities_list: @entity11 :: ('MESH:D005910', 'Disease') :: ['gliomas', 'GBM', 'glioma']

entities_list: @entity816 :: ('MESH:D001254', 'Disease') :: ['astrocytoma']

answer: @entity470 :: (1956,Gene) :: ['epidermal-growth-factor-receptor']


abstract: OBJECTIVES: @entity410 is a common presenting symptom of primary @entity1313 . There are no published studies regarding the roles of MicroRNA (miRNA) in @entity5 -related @entity302 . The authors set out to correlate @entity35585 expression in @entity11 @entity1 with pre-operative @entity410 and post-operative @entity410 control. METHODS: Twenty-three @entity1 with WHO grade II @entity816 and 83 similar @entity1 for independent validation were included. Follow-up visits regarding @entity410 prognosis were scheduled at 6 months. MiRNA profiling was used to identify differentially expressed miRNAs. The most important miRNA was determined by quantitative reverse-transcriptase polymerase chain reaction (q-PCR) in the validation cohort. Gene ontology (GO) analysis and whole genome mRNA profiling was performed to investigate the underlying biological processes. RESULTS: Array results showed that 30 miRNAs were overexpressed and 10 miRNAs were underexpressed (with more than 2 fold change) in @entity1 with pre-operative @entity410 . @entity35585 was validated in the independent validation cohort. @entity1 with good @entity410 prognosis exhibited low levels of @entity35585 expression compared with those who had poor @entity410 prognosis in the group without pre-operative @entity410 . Biological processes that relate to transcription and cell cycles were over-represented in the @entity35585 -associated gene expression signature. @entity35585 -associated gene expression profiling was characterized by enrichment of genes usually involved in cell proliferation. CONCLUSIONS: We have provided the first evidence that expression of @entity35585 was associated with the occurrence of pre-operative @entity410 in @entity11 , and may predict @entity410 prognosis in @entity1 without pre-operative @entity410 . Targeted treatments that decrease endogenous levels of @entity35585 might represent novel therapeutic strategies.

title: Significance of XXXX in @entity5 -related @entity302 of @entity1 with @entity11 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures', 'Seizure']

entities_list: @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumors']

entities_list: @entity11 :: ('MESH:D005910', 'Disease') :: ['low-grade gliomas', 'low-grade glioma']

entities_list: @entity816 :: ('MESH:D001254', 'Disease') :: ['astrocytomas']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

answer: @entity35585 :: (442920,Gene) :: ['miR-196b']


abstract: AIMS: To examine cardiovascular preventive and renal protective treatment for different ethnic groups with @entity6 in primary care. METHODS: The study population included @entity1 with @entity164 2 @entity6 attending an annual review in New Zealand primary care during 2004. Primary care data were linked to hospital admission data to identify previous @entity65 ( @entity65 ). For those without previous @entity65 , 5-year cardiovascular risk was calculated. Proportions on, and predictors of appropriate treatment according to guidelines were investigated. RESULTS: Data were available on 29,179 @entity1 . Maori and Pacific @entity1 had high rates of @entity28 , poor glycaemic control and @entity633 . Two thirds of all @entity1 with previous @entity65 (68% of Maori and 70% of Pacific) and 44% with high @entity65 risk received appropriate @entity65 treatment; 73% of Maori, 62% of Pacific and 65% of European @entity1 with @entity633 received ACE-inhibitors. Those with high @entity65 risk were more likely, and those that were young were less likely, to receive anti- @entity101 and lipid-lowering treatment after controlling for other factors. CONCLUSION: Maori and Pacific @entity1 were receiving similar high rates of appropriate @entity65 and renal preventive drug therapy to Europeans, but their prevalence of smoking, @entity28 , raised HbA1c and @entity633 were substantially higher. Non-drug components of preventive care also need to be addressed to reduce major ethnic disparities in @entity6 -related morbidity and mortality in New Zealand.

title: Cardiovascular risk management of different ethnic groups with XXXX 2 @entity6 in primary care in New Zealand.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'people']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity633 :: ('MESH:D000419', 'Disease') :: ['albuminuria']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['CVD', 'cardiovascular disease']

answer: @entity164 :: (MESH:D017827,Disease) :: ['type']


abstract: BACKGROUND: Recent data support primary plate fixation of displaced midshaft @entity174 . The safety and efficacy of this practice have not been well documented in @entity2587 . HYPOTHESIS: Plate fixation of @entity174 in @entity2587 is a safe and effective procedure, resulting in a reliable and timely return to play. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: A total of 29 @entity1 with displaced midshaft @entity174 from @entity2587 activity were treated with plate fixation between January 1, 2003 and December 31, 2008, including 1 @entity1 treated for each clavicle for separate injuries. All 29 @entity1 were contacted for follow-up. At a mean follow-up of 21 months, @entity1 completed a questionnaire focused on the time to return to athletics and treatment course. @entity1 also completed the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire. Radiographs were reviewed to identify @entity174 comminution, displacement, shortening, and angulation; radiographic union time; and malunion. RESULTS: All of the @entity1 (30/30 cases) returned to sports after open reduction internal fixation of their @entity174 . The mean time to return to play was 83 days with a range of 13 to 277 days. Seven (23%) of the cases returned to athletics at  <=6 weeks after surgery, and a total of 20 @entity1 (67%) returned at  <=12 weeks after surgery. All @entity1 (100%) were satisfied with their treatment. The QuickDASH scores revealed almost perfect recovery (mean score, 0.8 of 100). Four minor complications were identified. No @entity1 had a refracture, plate @entity174 , loss of fixation, nonunion, malunion, or deep wound @entity281 . CONCLUSION: Plate fixation of displaced @entity174 in @entity2587 is a safe procedure, resulting in a high satisfaction rating and minimal disability to the upper extremity. An early return (<6 weeks) to sports is possible after this treatment; however, the time to return is highly variable.

title: Return to XXXX activity after plate fixation of displaced midshaft @entity174 .

entities_list: @entity2587 :: ('MESH:D001265', 'Disease') :: ['athletic', 'athletes']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['clavicle fractures', 'fracture']

answer: @entity2587 :: (MESH:D001265,Disease) :: ['athletic']


abstract: BACKGROUND AND OBJECTIVES: The management of @entity75 has evolved to include endoscopic ampullectomy (EA) as a curative approach to @entity5 of the ampulla of Vater. With this change comes a need to risk-stratify @entity1 at initial diagnosis. MATERIALS AND METHODS: @entity1 with verified @entity75 (N = 50) were analyzed in a case-control design. We evaluated endoscopic ultrasound (EUS) data to define characteristics that yield a high sensitivity in selecting candidates for EA. RESULTS: Using data from previously published studies yielded a sensitivity of 0.765 in appropriately identifying the 34 surgical cases. Expanding these characteristics increased the sensitivity of EUS to 0.971 in identifying surgical candidates. Additionally, of advanced disease cases, the expanded characteristics correctly identified these cases with a sensitivity of 1.0-improved over 0.708 using prior published data. CONCLUSION: EA should be strongly considered if @entity75 are found to fit the following characteristics after EUS evaluation: lesion size <2.5 cm, invasion  <=4 mm, @entity384  <=3 mm,  <=T1 lesion, no lymph nodes present, and no ductal stent in place. Furthermore, EUS data can be used to identify all high-risk lesions. With these characteristics identified, clinicians are better able to risk-stratify @entity1 using EUS as either appropriate for or too high-risk for endoscopic resection.

title: Characteristic endoscopic ultrasound findings of XXXX that predict the need for surgical excision or endoscopic ampullectomy.

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['ampullary lesions']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['pancreatic duct dilatation']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers']

answer: @entity75 :: (MESH:D001927,Disease) :: ['ampullary lesions']


abstract: The therapeutic efficacy of @entity503 (CQ) and @entity1484 (SP) was determined over a 4 year period (1998-2001) in Bobo Dioulasso, Burkina Faso, with an analysis of the risk factors associated to treatment failures to the 2 drugs. In total, 2008 @entity1 (6 months-15 years old) attending in 4 health centres (1 urban and 3 rural) were included in the study. @entity1 were alternatively allocated to either CQ or SP The WHO 14-days in vivo field test was carried out. @entity1485 was measured at day 0 and 14. CQ treatment failure was 24.4% (229/940), most of them being late failures. Between 1998 and 2001 a significant increase in CQ treatment failure (p < 0.001) was observed. SP showed a good efficacy with a total treatment failure of 4.4% (33/749). However; a significant increase of resistance to this drug (p=0.001) was also observed between 1998 and 2001. Among @entity1 with @entity417 at day 0.85% (23/27) were no more anaemic by day 14 in the SP group, while in the CQ group the proportion was lower; 69% (27/39). However the difference between the two drugs was not significant (p > 0.1). Univariate analysis showed that the site, the age of @entity1 , the time of recruitment and the parasitaemia were significantly associated with CQ treatment failure. In the multivariate analysis these 4 variables remain significantly and independently associated with the risk of CQ treatment failure. After adjusting for the effect of the 3 other factors, the risk of treatment failure was reduced by half in rural area compared to urban area as well as in @entity1 of 5-15 years of age compared to those under 5. The risk of treatment failure was significantly increased in 2000-2001 (OR = 1.66, p < 0.05) as compared to the 2 previous years (1998-1999). It was also twice higher in @entity1 with parasitaemia > or = 16,000/microl than in those having a lower parasitaemia. For SP we have not observed such connexions with the univariate and multivariate analysis.

title: [In vivo sensitivity of Plasmodium faciparum to @entity503 and XXXX in the Bobo Dioulasso region (1998-2001): risk factors associated with treatments failures to the two drugs].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Children']

entities_list: @entity1484 :: ('MESH:C001205', 'Chemical') :: ['sulfadoxine-pyrimethamine']

entities_list: @entity503 :: ('MESH:D002738', 'Chemical') :: ['chloroquine']

answer: @entity1484 :: (MESH:C001205,Chemical) :: ['sulfadoxine pyrimethamine']


abstract: PURPOSE: Appendicostomy for antegrade continence enema is a minimally invasive surgical intervention that has helped many @entity1 with chronic @entity1142 . At our institution, since 2006, transcutaneous electrical stimulation (TES) has been trialed to treat @entity73 ( @entity73 ) in @entity1 . This retrospective audit aimed to determine if TES use affected appendicostomy-formation rates and to monitor changes in practice. We hypothesized that appendicostomy rates have decreased for @entity73 but not for other indications. METHODS: Appendicostomy-formation rate was determined for the 5 years before and after 2006. @entity1 were identified as @entity73 or non- @entity73 from nuclear transit scintigraphy and @entity1 records. RESULTS: Since 1999, 317 @entity1 were diagnosed with @entity73 using nuclear transit scintigraphy with 121 during 2001 to 2005 (24.2/year) and 147 during 2006 to 2010 (29.4/year). Seventy-four @entity1 had appendicostomy formation. For 2001 to 2005, appendicostomy-formation rates for @entity73 and non- @entity73 @entity1 were similar: 5.4 per year (n = 27) and 4.8 per year (n = 24), respectively. For 2006 to 2010, appendicostomy-formation rates were 1.2 per year (n = 6) for @entity73 and 3.2 per year (n = 16) for non- @entity73 (  (2), P = .04). CONCLUSION: Since 2006, appendicostomy-formation rates have significantly reduced in @entity73 but not in non- @entity73 @entity1 at our institute, coinciding with the introduction of TES as an alternative treatment for @entity73 . Transcutaneous electrical stimulation has not been tested on non- @entity73 @entity1 in this period.

title: The impact of transcutaneous electrical stimulation therapy on appendicostomy operation rates for XXXX with chronic @entity1142 --a single-institution experience.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Children', 'patient']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['STC', 'slow-transit constipation']

entities_list: @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: BACKGROUND: @entity1342 is a new local anaesthetic available for spinal and epidural anaesthesia. When new drugs are being introduced for spinal application, their effect on @entity602 ( @entity602 ) should be studied for safety and toxicological aspects. In the present study, @entity602 was studied after intrathecal (i.t.) application of @entity1342 and @entity1341 with and without @entity1425 . METHOD: @entity602 was measured continuously in spontaneously breathing, @entity4488 / @entity3727 anaesthetized @entity35 , using laser-Doppler flowmetry technique. The spinal cord was exposed by laminectomy at the L1-L2 level, and a laser-Doppler probe was placed over the dorsal horn, allowing on-line registration of @entity602 in a tissue hemisphere of 1-2 mm. Relative changes in @entity602 were then measured on-line after i.t. administration of increasing doses of @entity1342 , @entity1341 or @entity1341 with @entity1425 . RESULTS: @entity1342 and @entity1341 decreased @entity602 in a dose-dependent manner. In contrast, the reduction in @entity602 produced by @entity1341 + @entity1425 (Bupi + Epi) was equal for all doses of @entity1341 . The order of magnitude of @entity602 decreases was Bupi + Epi > @entity1342 > @entity1341 . The maximal decrease in @entity602 at the highest concentration given (10 mg/ml) was 37 +/- 6% for @entity1342 , 27 +/- 7% for @entity1341 and 40 +/- 6% for @entity1341 + @entity1425 . CONCLUSION: @entity1342 and @entity1341 produce a dose-related, transient decrease in @entity602 following i.t. administration in anaesthetized @entity35 . However, the decrease in @entity602 produced by both @entity1342 , when @entity1425 was added in a concentration of 5 micrograms/ml. These results suggest that @entity1342 , like @entity1341 , may be used for spinal anaesthesia without important effects on @entity602 .

title: Spinal cord blood flow after intrathecal injection of XXXX and @entity1341 with or without @entity1425 in @entity35 .

entities_list: @entity1425 :: ('MESH:D004837', 'Chemical') :: ['epinephrine']

entities_list: @entity602 :: ('MESH:D013118', 'Disease') :: ['SCBF', 'spinal cord blood flow']

entities_list: @entity1342 :: ('MESH:C037663', 'Chemical') :: ['ropivacaine', 'Ropivacaine']

entities_list: @entity1341 :: ('MESH:D002045', 'Chemical') :: ['bupivacaine']

entities_list: @entity4488 :: ('MESH:D004737', 'Chemical') :: ['enflurane']

answer: @entity1342 :: (MESH:C037663,Chemical) :: ['ropivacaine']


abstract: BACKGROUND: @entity101 and increased blood @entity413 are associated with subclinical @entity8 , @entity731 and with low @entity251 values. Low @entity251 in @entity1 is often accompanied by increased levels of @entity53 . OBJECTIVES AND METHODS: In this study, the association between @entity53 , subclinical @entity8 and @entity731 in African and white @entity1 in a South African cohort was investigated. Cardiovascular variables were studied by means of B-mode ultrasound and ambulatory blood pressure (BP) monitoring. The sex hormones and other biochemical values were measured from fasting venous blood and overnight urine samples. The ethnic groups were stratified into low and high @entity251 groups by means of median split. RESULTS: The low @entity251 African group demonstrated a higher cardiovascular risk compared with the low @entity251 white @entity1 with 91% being @entity101 and having increased albumin-to-creatinine ratio (ACR), left carotid intima-media thickness (L-CIMTf) and @entity53 -to- @entity251 ratio. In the low- @entity251 African @entity1 , @entity53 explained 33% of the variance in ACR, whereas the @entity53 -to- @entity251 ratio explained 22% of the variance in L-CIMTf, respectively. @entity53 -to- @entity251 ratio was positively associated with ACR in the low @entity251 whites. CONCLUSION: We conclude that increased levels of @entity53 may play a role in the development of subclinical @entity8 in both African and white @entity1 as well as @entity731 in low- @entity251 African @entity1 .

title: Sex hormones associated with subclinical @entity8 and XXXX in South African @entity1 : the SABPA study.

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['kidney damage']

entities_list: @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive', 'Hypertension']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol', 'Estradiol']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity731 :: (MESH:D050197,Disease) :: ['atherosclerosis']


abstract: STUDY DESIGN: A cross-sectional and prospective longitudinal study on the anthropometric parameters and growth pattern of @entity1 with @entity1615 ( @entity1615 ). OBJECTIVE: To investigate the growth pattern of @entity1 with @entity1615 with different severities, using cross-sectional and prospective longitudinal data set in comparison with age-matched healthy controls. SUMMARY OF BACKGROUND DATA: @entity1615 occurs in @entity1 during their pubertal growth spurt. Although there is no clear consensus on the difference in body height between @entity1 with @entity1615 and healthy controls, it is generally thought that the development and curve progression in @entity1 with @entity1615 is closely associated with their growth rate. There is no concrete prospective longitudinal study to document clearly the growth pattern and growth rate of subjects with @entity1615 . METHODS: A total of 611 @entity1 with @entity1615 and 296 healthy age-matched controls were included in the study and among them, 194 @entity1 with @entity1615 and 116 healthy controls were followed up until skeletal maturity. The @entity1 with @entity1615 were grouped into moderate (AIS20) and severe curve (AIS40) groups on the basis of maximum curve magnitude at skeletal maturity. Clinical data and detailed anthropometric parameters were recorded. In the cross-sectional analysis, the groups of subjects were compared within different age groups (from the age of 12-16 yr). In the longitudinal study, linear mixed modeling with respect to age or years since menarche was employed to formulate the growth trajectory of different anthropometric parameters. RESULTS: In the cross-sectional analysis, the @entity1 with @entity1615 were generally taller, with longer arm span and lower body mass index than the healthy controls. The @entity1 with AIS40 were found to be significantly shorter in height (P = 0.006) and arm span (P = 0.025) at the age of 12 years but caught up and overtook the control group at the age of 14 to 16 years. In the longitudinal study, the average growth rate of arm span in @entity1 with AIS40 was significantly higher than that in @entity1 with AIS20 (> 30%) (P = 0.004) and controls (> 70%) (P = 0.0004). The age of menarche of @entity1 with AIS40 was significantly delayed by 5.9 months and 3.8 months when compared with the control group and @entity1 with AIS20, respectively (P < 0.05). CONCLUSION: The growth patterns of @entity1 with @entity1615 with confirmed curve severities were significantly different from healthy age-matched controls. @entity1 with severe @entity1615 had delayed menarche with faster skeletal growth rate during the age of 12 to 16 years. Monitoring the rate of change of arm span of @entity1 with @entity1615 could be an important additional clinical parameter in helping predict curve severity in @entity1 with @entity1615 .

title: Abnormal skeletal growth patterns in XXXX --a longitudinal study until skeletal maturity.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'girls', 'Girls']

entities_list: @entity1615 :: ('OMIM:181800', 'Disease') :: ['AIS', 'adolescent idiopathic scoliosis']

answer: @entity1615 :: (OMIM:181800,Disease) :: ['adolescent idiopathic scoliosis']


abstract: INTRODUCTION: In conjunction with the NILVAD trial, a European Multicentre Double-Blind Placebo Controlled trial of @entity17425 in Mild-to-Moderate @entity195 ( @entity195 ), there are four NILVAD substudies in which eligible NILVAD @entity1 are also invited to participate. The main NILVAD protocol was previously published in BMJ Open (2014). The objectives of the NILVAD substudies are to determine whether frailty, cerebrospinal fluid (CSF), blood biomarker profile and @entity2204 ( @entity2204 ) status predict response to @entity17425 , and to investigate the effect of @entity17425 on cerebral blood flow and blood biomarkers. METHODS AND ANALYSIS: All @entity1 who fulfil criteria for the main NILVAD study are eligible for participation in the NILVAD substudies. Participation is subject to informed consent and whether the substudy is available at a particular NILVAD study site. Each substudy entails extra measurements during the course of the main NILVAD study. For example, in the blood and genetic biomarkers substudy, extra blood (30   mL) will be collected at week 0, week 13, week 52 and week 78, while in the cerebral blood flow substudy, @entity1 will receive an MRI and transcranial Doppler measurements at week 0, week 26 and week 78. In the CSF substudy, 10   mL CSF is collected at week 0 and week 78. ETHICS AND DISSEMINATION: All NILVAD substudies and all subsequent amendments have received ethical approval within each participating country, according to national regulations. Each @entity1 provides written consent to participate. All @entity1 remain anonymised throughout and the results of each substudy will be published in an international peer reviewed journal. TRIAL REGISTRATION NUMBER: EUDRACT 2012-002764-27; Pre-results.

title: European multicentre double-blind placebo-controlled trial of @entity17425 in mild-to-moderate XXXX -the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'participant']

entities_list: @entity17425 :: ('MESH:C035100', 'Chemical') :: ['Nilvadipine']

entities_list: @entity2204 :: ('348', 'Gene') :: ['APOE', 'Apolipoprotein E']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's disease"]

answer: @entity195 :: (MESH:D000544,Disease) :: ['Alzheimer's disease']


abstract: A fifty-nine-year-old alcoholic @entity1 with severe hypoglycemic @entity75 was examined using sequential CT scans of the brain (CT). Twenty-seven hours after the attack, which resulted in a @entity772 state, CT disclosed multiple low density areas throughout the cerebral cortex which resembled multiple cortical @entity1188 . CT obtained four days after the ictus demonstrated more prominent low density areas in the cerebral cortex, @entity2657 and partial cortical enhancement after administration of contrast medium. Sixteen days after the ictus, the multiple low density areas in the cerebral cortex disappeared. Enhanced CT on day 23 demonstrated marked gyral enhancement throughout the cerebral cortex. Thereafter diffuse brain @entity194 progressed rapidly as demonstrated by MRI on day 82 which showed extensive cortical and subcortical @entity194 particularly in the frontoparietal and parieto-occipital regions bilaterally with dilated lateral ventricles. @entity4053 and @entity519 have long been thought to give rise to similar types of @entity75 based on neuropathological observations. But it has recently been shown that they are quite different based on neurochemical and neurophysiological findings. Numerous previously reported autopsy cases of @entity4053 confirm these findings which are neuropathologically similar to the multiple @entity1188 seen in the present case. We conclude that the acute cortical changes of the present case are specific for hypoglycemic @entity75 . The findings indicate that the basic mechanisms operating in @entity4053 and @entity519 are different.

title: [Hypoglycemic @entity75 demonstrating generalized multiple cortical XXXX --sequential CT findings].

entities_list: @entity2657 :: ('MESH:D001929', 'Disease') :: ['diffuse cerebral edema']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['encephalopathy', 'brain damage']

entities_list: @entity772 :: ('MESH:D003128', 'Disease') :: ['comatose']

entities_list: @entity4053 :: ('MESH:D007003', 'Disease') :: ['Hypoglycemia', 'hypoglycemia']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarctions', 'infarction']

answer: @entity1188 :: (MESH:D007238,Disease) :: ['infarctions']


abstract: AIMS: To quantify the variation in @entity82 , fat and muscle within the walls of both ventricles and within the different regions of the heart from six @entity1 dying suddenly of @entity4128 ( @entity4128 ) aged 20-60 years. METHODS: Seven heart regions were examined both macroscopically and histologically using the Picro-Sirius red stain. Quantification of @entity82 , fat and muscle was performed in each region and transmural layer using grid counting. RESULTS: There were macroscopic changes in all examined hearts. A higher percentage of fat with less @entity82 and muscle was observed within the right ventricle of the older @entity1 . The left ventricle had more pathology in the older age group. Statistical differences in pathology in the heart were found. Fat predominated in the epicardial layer in the right and left ventricles of all @entity1 , while the interventricular septum was the least affected. CONCLUSIONS: In @entity4128 , the pathology varies with age in both ventricles, @entity82 being the earliest @entity66 , with fatty infiltration evolving later. It should be labelled arrhythmogenic @entity67 because of biventricular involvement. Histopathologists should therefore sample from whole slices of the heart, so that all the changes can be observed.

title: Spectrum of pathological changes in both ventricles of @entity1 dying suddenly with XXXX . Relation of changes to age.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4128 :: ('MESH:D019571', 'Disease') :: ['arrhythmogenic right ventricular dysplasia', 'ARVD']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['hallmark of disease']

entities_list: @entity67 :: ('MESH:D018754', 'Disease') :: ['ventricular dysplasia']

answer: @entity4128 :: (MESH:D019571,Disease) :: ['arrhythmogenic right ventricular dysplasia']


abstract: The main controversies regarding tubular apocrine @entity652 and @entity652 are whether they are two distinct entities or are the very same @entity5 , and if so, which lineage of differentiation (apocrine versus eccrine) it pursues. We report two cases of @entity652 with follicular and, in one case, additionally, sebaceous differentiation. The features in both cases indicated apocrine differentiation of the tubular component. One @entity1 was a 60-year-old @entity1 with a 1-year history of a solitary nodule on the scalp. The other @entity1 was a 48-year-old @entity1 with a solitary nodule of unknown duration located on the back. In both @entity1 , the @entity5 were surgically removed. The @entity1 were alive and well 2.5 and 2 years after surgery, respectively. The histologic features that both cases had in common included the combination of a @entity652 , foci of follicular differentiation, and areas of @entity1544 . In case 1, follicular differentiation was seen in the form of strands of basaloid cells surrounded by a stroma resembling the @entity2085 . Some aggregates of basaloid cells were juxtaposed with small collections of plump fibroblasts, imparting a resemblance to rudimentary follicular germs associated with follicular papillae. Many minute lumens surrounded by more eosinophilic cells were seen within the strands. In case 2, follicular differentiation was seen as several infundibulocystic structures surrounded by isthmic epithelium housing scattered mature sebocytes. In addition, there were areas reminiscent of desmoplastic trichoepithelioma (columnar trichoblastoma). In both cases, the areas with @entity1544 were represented by solid nodules that were mostly devoid of lumens and a peripheral basal/myoepithelial cell layer. In conclusion, these two cases of cutaneous @entity652 with accompanying follicular and sebaceous differentiation give further support to the proposition that the majority of these @entity5 have apocrine differentiation. Rare cases occurring in the sites normally devoid of apocrine glands may represent the eccrine counterpart.

title: Tubular XXXX of the skin with follicular and sebaceous differentiation: A report of two cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patients', 'patient']

entities_list: @entity2085 :: ('MESH:D020964', 'Disease') :: ['embryonic perifollicular sheath']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors', 'neoplasms']

entities_list: @entity1544 :: ('MESH:D018307', 'Disease') :: ['immature squamous metaplasia']

entities_list: @entity652 :: ('MESH:D000236', 'Disease') :: ['papillary eccrine adenoma', 'tubular adenoma', 'adenoma']

answer: @entity652 :: (MESH:D000236,Disease) :: ['adenoma']


abstract: OBJECTIVES: @entity2489 ( @entity2489 ) is an important cause of morbidity and mortality in critical care settings. Acinetobacter has become a leading cause of @entity2489 . In particular, the appearance and spread of multidrug-resistant Acinetobacter is of great concern. In this study, we examined the effect of the antioxidant @entity46808 on Acinetobacter @entity19 @entity55 in hyperoxic conditions in order to simulate @entity2489 . METHODS: Acinetobacter was administered intranasally to BALB/c @entity19 kept in hyperoxic conditions. At designated timepoints, bacterial number, cytokine production and histopathological findings in the lungs were examined. The effects of @entity46808 on survival rates, lung bacterial burdens and the phagocytic activities of alveolar macrophages were evaluated. RESULTS: Drastic decreases in survival were observed when the infected @entity19 were kept in hyperoxic conditions (P < 0.001). Significant differences in pulmonary bacterial number and neutrophil accumulation were observed between @entity19 kept in hyperoxic or normoxic conditions on day 3. Although all @entity19 infected with Acinetobacter spp. and kept in hyperoxic conditions died by day 3, @entity46808 treatment significantly improved survival (60% survival on day 7, P < 0.01). @entity46808 treatment decreased the lung bacterial burden on days 2 and 3. Finally, improved uptake of @entity2823 -labelled beads by alveolar macrophages from @entity19 treated with @entity46808 and kept in hyperoxic conditions was noted. CONCLUSIONS: These results suggest that @entity871 increases mortality in @entity19 with @entity55 and that @entity46808 improves survival by increasing the phagocytic activity of alveolar macrophages in @entity19 kept in hyperoxic conditions.

title: Protective effect of XXXX on @entity55 in hyperoxic conditions.

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['Acinetobacter pneumonia', 'pneumonia']

entities_list: @entity871 :: ('MESH:D018496', 'Disease') :: ['hyperoxia']

entities_list: @entity2489 :: ('MESH:D053717', 'Disease') :: ['Ventilator-associated pneumonia', 'VAP']

entities_list: @entity46808 :: ('MESH:C029536', 'Chemical') :: ['Procysteine', 'procysteine']

answer: @entity46808 :: (MESH:C029536,Chemical) :: ['procysteine']